Valuation Vertex Pharmaceuticals Incorporated

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 24/07/2026 BST			5-day change	1st Jan Change
477.36 ^USD	+0.90%		-1.71%	+5.29%

07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	55,834	74,127	104,849	103,707	115,026	121,157	-	-
Change	-	32.76%	41.44%	-1.09%	10.91%	5.33%	-	-
Enterprise Value (EV) ¹	48,309	63,349	93,630	97,591	108,418	107,414	102,545	97,516
Change	-	31.13%	47.8%	4.23%	11.09%	-0.93%	-4.53%	-4.9%
P/E	24.4x	22.5x	29.3x	-194x	29.6x	27.2x	24x	19.9x
PBR	5.53x	5.33x	5.96x	6.4x	6.17x	5.47x	4.53x	3.81x
PEG	-	0.5x	3.51x	2x	-0x	1.9x	1.8x	1x
Capitalization / Revenue	7.37x	8.3x	10.6x	9.41x	9.58x	9.29x	8.44x	7.53x
EV / Revenue	6.38x	7.09x	9.49x	8.86x	9.03x	8.23x	7.15x	6.06x
EV / EBITDA	10.8x	12.8x	20.6x	108x	19.8x	18.6x	15.4x	12.8x
EV / EBIT	11.1x	13.2x	21.4x	140x	20.6x	19.4x	16.2x	13.2x
EV / FCF	20.1x	16.1x	28.1x	-123x	33.9x	21.7x	21.1x	19x
FCF Yield	4.99%	6.2%	3.56%	-0.81%	2.95%	4.61%	4.75%	5.26%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	9.01	12.82	13.89	-2.08	15.32	17.54	19.9	24.01
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	7,574	8,931	9,869	11,020	12,001	13,046	14,347	16,084
EBITDA ¹	4,470	4,941	4,556	902.8	5,473	5,789	6,650	7,648
EBIT ¹	4,344	4,793	4,375	695.6	5,263	5,525	6,331	7,406
Net income ¹	2,342	3,322	3,620	-535.6	3,953	4,518	5,136	6,175
Net Debt ¹	-7,525	-10,778	-11,218	-6,116	-6,608	-13,743	-18,611	-23,641
Reference price ²	219.60	288.78	406.89	402.70	453.36	477.36	477.36	477.36
Nbr of stocks (in thousands)	254,252	256,691	257,683	257,529	253,719	253,805	-	-
Announcement Date	26/01/22	07/02/23	05/02/24	10/02/25	12/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
VERTEX PHARMACEUTICALS INCORPORATED	27.21x	8.23x	18.55x	-.--%	121B
ELI LILLY AND COMPANY	35.7x	12.68x	26.75x	0.57%	1,067B
JOHNSON & JOHNSON	28.24x	6.45x	17.87x	2.04%	635B
ABBVIE INC.	33.87x	7.65x	15.73x	2.65%	458B
ROCHE HOLDING AG	19.22x	4.69x	11.57x	2.82%	347B
NOVARTIS AG	21.56x	5.71x	14.24x	2.81%	295B
ASTRAZENECA PLC	21.1x	4.45x	12.31x	1.98%	262B
NOVO NORDISK A/S	14.14x	5.26x	10.84x	3.54%	216B
AMGEN INC.	24.66x	6.48x	11.43x	2.68%	203B
GILEAD SCIENCES, INC.	-46.58x	5.59x	30.88x	2.55%	161B
Average	17.91x	6.72x	17.02x	2.16%	376.42B
Weighted average by Cap.	24.96x	7.96x	18.70x	1.9%